Scroll
To Top

Archives for: May 31st, 2017

Orphan Drug Act at 30: Will Success Become Too Expensive?

Written by Steven A. Grossman on January 19, 2013

Reprinted with permission from FDA Matters:  By Steven Grossman

The Orphan Drug Act (ODA) turned 30 this month, demonstrating that good laws really can have an enduring impact.  Amidst the celebrations, a reporter asked me a provocative question:  Can we afford more orphan drugs costing hundreds of… Read More